On October 30, 2017, Health Canada published the final version of the following guidance documents and template:
- Guidance Document: Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs)
- Addendum - Quality (Chemistry and Manufacturing) Guidance: Questions and Answers
- Glossary of Quality Terms
- Guidance Document: Certified Product Information Document – Chemical Entities
- Certified Product Information Document – Chemical Entities (CPID-CE) Template
According to the announcement, the Guidance Documents implement new requirements for New Drug Submissions and Abbreviated New Drug Submissions, including requirements for stability studies on three batches of product for existing drugs, commercial scale batches and pilot batch sizes for certain products. The changes will be implemented in a phased-in approach, with the General Quality Guidance requirements being implemented on January 30, 2018, and the new stability requirements and requirements for commercial scale and pilot scale batches becoming fully implemented on October 30, 2019. After October 30, 2019, a submission must contain at least 6 months of stability data on at least 3 primary batches of the drug substance and drug product.
Related Publications & Articles
-
CADTH announces the launch of Post-Market Drug Evaluation Program
On September 1, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of its Post-Market Drug Evaluation Program.Read More -
Health Canada releases new guidance document on clinical evidence requirements for medical devices
On November 15, 2022, Health Canada released a new guidance document, “ Guidance on clinical evidence requirements for medical devices.” In it, Health Canada provides guidance on clinical evidence req...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More